Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer: Results of a Phase I/II Trial
The median time to treatment failure and overall survival of 15.9 months and 43.5 months, respectively, are consistent with our historical data in patients receiving i.p. platinum-based regimens for consolidation. The fibrotic changes seen in explored patients suggest local toxicity of this combination. The absolute benefit of i.p. consolidation requires randomized trials to assess efficacy.